Exposure and Response Prevention for Disease

Phase-Based Progress Estimates
Disease+6 More
Exposure and Response Prevention - Behavioral
All Sexes
What conditions do you have?

Study Summary

This trial will compare the outcomes of exposure and response prevention (ERP), the sole evidence-based psychotherapy for OCD, to those of a control condition among Veterans with OCD.

Eligible Conditions
  • Disease
  • Comorbid Post-Traumatic Stress Disorder and OCD
  • Obsessive-Compulsive Disorder

Treatment Effectiveness

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: Baseline, Post Treatment (4-6 Months after Randomization), 6 Months Post Treatment

Month 6
Adult OCD Impact Scale (AOIS) - Change
Columbia Suicide Severity Rating Scale (C-SSRS) - Suicidality - Change
Generalized Anxiety Disorder-7 scale (GAD-7) - Anxiety Symptoms - Change
Obsessive-Compulsive Inventory, Revised (OCI-R) - Change
PTSD Checklist (PCL-5) - PTSD Symptoms - Change
Mental Depression
Quality of Life Enjoyment and Satisfaction Questionnaire, short form (QLESQ-SF) - Change
Work and Social Adjustment Scale (WSAS) - Change
Yale-Brown Obsessive Compulsive Scale, self-report form (Y-BOCS) - Change
Month 6
Quality of Life and Functional Status (SF-12V) - Change

Trial Safety

Trial Design

1 Treatment Group

Exposure and Response Prevention (ERP)
1 of 1
Experimental Treatment

160 Total Participants · 1 Treatment Group

Primary Treatment: Exposure and Response Prevention · No Placebo Group · N/A

Exposure and Response Prevention (ERP)
Experimental Group · 1 Intervention: Exposure and Response Prevention · Intervention Types: Behavioral
First Studied
Drug Approval Stage
How many patients have taken this drug
Exposure and Response Prevention
Completed Phase 4

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, post treatment (4-6 months after randomization), 6 months post treatment

Who is running the clinical trial?

VA Office of Research and DevelopmentLead Sponsor
1,472 Previous Clinical Trials
2,741,534 Total Patients Enrolled
83 Trials studying Disease
12,391 Patients Enrolled for Disease
Terri L. Fletcher, PhDPrincipal InvestigatorMichael E. DeBakey VA Medical Center, Houston, TX
1 Previous Clinical Trials
225 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are willing to participate in ERP.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 24th, 2021

Last Reviewed: October 28th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.